CRON vs TRLV vs VRNO Stock Comparison

Cronos, Trulieve Cannabis and Verano Holdings Prices as of Nov 13, 2026 Peers: Industry group
CRON Cronos Group Inc.
$3.38 +7.0% 1M +36.3% 1Y
Market cap
$1.21B
P/E
21.0x
Revenue (TTM)
$271.85M
Div. yield
–
Cannabis Consumer Staples
5 wins
VRNO Verano Holdings Corp.
$4.21 -19.3% 1M -28.6% 1Y
Market cap
$290.29M
P/E
–
Revenue (TTM)
$845.15M
Div. yield
–
Cannabis Consumer Staples
2 wins

Head to Head

9 decided of 12

Cronos leads on 5 of the 12 questions below (Cronos 5, Trulieve Cannabis 2, Verano Holdings 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCRONTRLVVRNOLeader
Larger companyMarket capitalisation $1.21B $2.04B $290.29M TRLV
Cheaper on earningsLower P/E, profitable companies only 21.0x -4.6x -1.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.9x — — –
Faster revenue growthRevenue growth, trailing twelve months +54.3% -9.1% +1.4% CRON
More profitableNet margin, trailing twelve months 21.3% -41.2% -25.9% CRON
Better return on capitalReturn on invested capital — -29.0% -12.2% VRNO
Less leveragedLower net debt / EBITDA — 0.8x -24.6x VRNO
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +36.3% +77.1% -28.6% TRLV
Better 5-year returnAnnualised price return, 5 years -11.6%/yr -18.9%/yr -42.9%/yr CRON
Less volatileAnnualised volatility, 1 year 40.0% 100.6% 119.1% CRON
Higher overall scoreMean of the five percentile scores vs peers 88/100 42/100 46/100 CRON

Percentile Scorecard

CRONTRLVVRNO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCRONTRLVVRNO
Valuation 68 #13 of 39 42 #23 of 39 21 #31 of 39
Growth 97 #2 of 37 14 #32 of 37 22 #29 of 37
Profitability 81 #8 of 37 33 #25 of 37 42 #22 of 37
Financial Health 100 #1 of 41 80 #9 of 41 65 #15 of 41
Shareholder Returns 94 #2 of 17 – 81 #4 of 17
Overall 88 42 46
  • CRON ranked among 41 companies in Tobacco and Cannabis
  • TRLV ranked among 41 companies in Tobacco and Cannabis
  • VRNO ranked among 41 companies in Tobacco and Cannabis

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCRONTRLVVRNOSPY
1 month +7.0%+9.1%-19.3% -2.0%
3 months +7.6%+12.8%-30.0% -2.8%
6 months +28.5%+50.0%-20.6% +2.0%
Year to date +28.5%+25.3%-33.2% +10.6%
1 year +36.3%+77.1%-28.6% +12.2%
3 years +69.0%+96.2%-81.1% +68.1%
3 years, per year +19.1%+25.2%-42.7% +18.9%
5 years -46.0%-64.8%-93.9% +61.4%
5 years, per year -11.6%-18.9%-42.9% +10.1%

Risk

MeasureCRONTRLVVRNOSPY
Volatility, 1Y 40.0%100.6%119.1% 13.6%
Downside volatility, 1Y 36.1%84.7%112.9% 13.9%
Beta vs S&P 500, 1Y 0.350.660.85 1.00
Return / volatility, 1Y 0.910.77-0.24 0.90
Max drawdown, 5Y -72.7%-89.5%-96.4% -25.4%
From 52-week high -9.1%-16.2%-51.6% -3.2%
52-week high $3.72$13.00$8.70 $779.14
52-week low $2.30$4.76$3.95 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCRONTRLVVRNO
P/E now vs peer median 21.5xmedian 18.9x -4.7xmedian 18.9x -1.4xmedian 18.9x
P/S now vs peer median 4.6xmedian 0.7x 1.7xmedian 0.7x 2.2xmedian 0.7x
EV/EBITDA now vs peer median 22.2xmedian 11.5x -9.8xmedian 11.5x -181.0xmedian 11.5x
P/FCF now vs peer median 19.0xmedian 14.4x 9.9xmedian 14.4x 29.3xmedian 14.4x
P/B now vs peer median 1.1xmedian 0.9x 2.4xmedian 0.9x 2.7xmedian 0.9x
PEG now vs peer median 0.59median 1.00 -0.48median 1.00 0.02median 1.00

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCRONTRLVVRNO
Revenue $271.85M $1.08B $845.15M
Gross profit $96.08M $655.56M $404.41M
Operating income $7.10M -$277.01M -$129.43M
Net income $67.38M -$446.60M -$218.71M
Free cash flow $65.38M $188.18M $62.34M
R&D $5.35M – –
EPS (diluted) $0.16 $-2.22 $-2.99
Cash & equivalents $411.19M $326.69M $102.05M
Total debt – $186.66M $390.18M
Shares (diluted) 370.72M 200.61M 73.12M
Enterprise value -$1.98B $782.69M -$53.71M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCRONTRLVVRNO
P/E 21.5x -4.7x -1.4x
P/FCF 19.0x 9.9x 29.3x
P/Operating cash flow 15.3x 7.7x 16.4x
P/S 4.6x 1.7x 2.2x
P/B 1.1x 2.4x 2.7x
P/Tangible book 1.1x 4.3x 13.5x
EV/EBITDA 22.2x -9.8x -181.0x
EV/EBIT 70.6x -6.2x -16.3x
EV/Revenue 1.8x 1.6x 2.5x
EV/FCF 7.7x 9.1x 33.9x
EV/Operating cash flow 6.2x 7.1x 18.9x
PEG (3Y EPS CAGR) 0.59 -0.48 0.02

Growth

14 metrics
MetricCRONTRLVVRNO
Revenue growth (1Y) 54.3% -9.1% 1.4%
Revenue CAGR (3Y) 33.1% -1.8% -3.0%
Gross profit growth (1Y) 67.4% -9.3% -2.6%
Gross profit CAGR (3Y) 104.4% 3.5% -4.3%
Operating income growth (1Y) 133.4% -313.9% 48.9%
Operating income CAGR (3Y) 27.6% -4.1% -8.1%
Net income growth (1Y) 58.3% -218.5% 37.0%
Net income CAGR (3Y) 37.9% 8.4% 5.1%
EPS growth (1Y) 66.4% -218.8% -211.7%
EPS CAGR (3Y) 36.6% 9.7% -58.9%
Operating cash flow growth (1Y) 272.8% -0.7% 35.3%
Operating cash flow CAGR (3Y) 43.7% 24.6% 1.6%
Free cash flow growth (1Y) 1,317% 27.0% 70.8%
Free cash flow CAGR (3Y) 40.3% 46.3% -4.0%

Profitability

14 metrics
MetricCRONTRLVVRNO
Gross margin 35.3% 60.6% 47.9%
EBITDA margin 8.3% -16.1% -1.4%
Operating margin 2.6% -25.6% -15.3%
Pretax margin 22.1% -30.4% -22.0%
Net margin 21.3% -41.2% -25.9%
FCF margin 24.0% 17.4% 7.4%
Operating cash flow margin 29.8% 22.4% 13.2%
Return on equity 6.1% -58.1% -32.5%
Return on assets 5.8% -21.3% -12.8%
Return on invested capital – -29.0% -12.2%
Return on capital employed 0.6% -13.9% -8.1%
Asset turnover 0.2x 0.5x 0.5x
Cash conversion (OCF / net income) 1.2x -0.5x -0.5x
Stock comp / revenue 2.4% 1.9% 1.3%

Financial Health

11 metrics
MetricCRONTRLVVRNO
Debt / assets – 8.8% 22.9%
Debt / equity – 0.2x 0.6x
Net debt / EBITDA – 0.8x -24.6x
Debt / FCF – 1.0x 6.3x
Liabilities / assets 6.1% 63.6% 60.6%
Equity / assets 93.9% 36.4% 39.4%
Interest coverage – -5.3x –
Current ratio 12.7x 5.5x 3.6x
Quick ratio 11.6x 3.4x 1.1x
Cash ratio 11.0x 3.2x 0.9x
Altman Z-score 11.79 0.30 0.63

Shareholder Returns

7 metrics
MetricCRONTRLVVRNO
Dividend yield – – –
Net buyback yield 3.7% – 0.2%
Shareholder yield 3.7% – 0.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCRONTRLVVRNO
Forward P/E 19.9xFY2026 – –
EPS, next fiscal year $0.17FY2026 $-1.96FY2026 $-0.42FY2026
EPS growth, the year after +11.8% – –
Revenue, next fiscal year $218.83MFY2026 $974.80MFY2026 $800.50MFY2026
Revenue growth, next FY +49.3%FY2026 -17.4%FY2026 -2.6%FY2026
Revenue growth, the year after +22.5% +0.4% +9.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCRONTRLVVRNO
Held by institutions 12.8% 18.1% 0.2%
Institutions holding 197 125 1
Change in shares held, QoQ -2.5% – –
Institutions buying 71 121 0
Institutions selling 41 1 1
Buyers to sellers 1.73 121.00 0.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CRONTRLVVRNO
CRON 1.00 0.48 0.47
TRLV 0.48 1.00 0.77
VRNO 0.47 0.77 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CRON, TRLV and VRNO?

Trulieve Cannabis (TRLV) is the largest by market capitalisation: Cronos (CRON) $1.21B, Trulieve Cannabis (TRLV) $2.04B, Verano Holdings (VRNO) $290.29M.

Which company is growing faster?

Cronos (CRON) grew revenue fastest over the trailing twelve months: Cronos (CRON) +54.3%, Trulieve Cannabis (TRLV) -9.1%, Verano Holdings (VRNO) +1.4%.

Which company is more profitable?

Cronos (CRON) has the highest net margin (Cronos (CRON) 21.3%, Trulieve Cannabis (TRLV) -41.2%, Verano Holdings (VRNO) -25.9%). On return on invested capital, Verano Holdings (VRNO) leads (Trulieve Cannabis (TRLV) -29.0%, Verano Holdings (VRNO) -12.2%).

Which stock has performed better?

Over the past year Trulieve Cannabis (TRLV) returned the most: Cronos (CRON) +36.3%, Trulieve Cannabis (TRLV) +77.1%, Verano Holdings (VRNO) -28.6%. Over five years, Cronos (CRON) compounded fastest (Cronos (CRON) -11.6%/yr, Trulieve Cannabis (TRLV) -18.9%/yr, Verano Holdings (VRNO) -42.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Cronos (CRON) has been the steadiest (Cronos (CRON) 40.0%, Trulieve Cannabis (TRLV) 100.6%, Verano Holdings (VRNO) 119.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CRON, TRLV and VRNO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cronos (CRON) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.